About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Rituximab in Metastatic Melanoma

Rituximab in Metastatic Melanoma

NCT01032122·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Medical University of Vienna

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologically verified non-ocular melanoma stage IIIc/IV, no evidence of disease

You may not be if

ECOG (Eastern Cooperative Oncology Group) performance status \> 2
Ocular melanoma
Immunodeficiency syndromes or hypogammaglobulinaemia
Active autoimmune diseases
Treatment with immunosuppressive agents other than steroids
Depressed bone marrow function (Leukopenia \<3000, platelet count \<100.000)
Cardiac insufficiency NYHA (New York Heart Association) IV
active Hepatitis B,C, or HIV infection
Pregnancy or lactation
Interstitial pulmonary disease
Former treatment with anti-CD20 antibody

The record

StatusTerminated

PhasePhase 1

Taking part9

StartedOct 2007

UpdatedApr 25, 2013

Conditions

Metastatic Melanoma

Where1

General Hospital Vienna, Dep. of Dermatology, Division of Immunology and Infectious Diseases
Vienna, Austria